demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
neutralizing antibody
casirivimab/imdevimab (Ronapreve) Somersan-Karakaya ...

1 studies excluded by filtering options 0

9481 Kim, 2022 000selection pending